Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least a BTK inhibitor and a BCL-2 inhibitor. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRIX:
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Nurix Therapeutics initiated with a Buy at UBS
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
- Nurix Therapeutics Appoints Anil Kapur to Board
- Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
